Vaxcyte's stock flat as biotech preps to complete $1.42 billion stock offering
By Ciara Linnane
Vaxcyte Inc.'s stock was flat on Friday, as the company prepared to complete a stock offering that is expected to generate $1.42 billion in proceeds.
The company is taking advantage of a 39% jump in its stock this week after it announced positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine candidate in adults aged 50 and older.
The San Carlos, Calif-based biotech (PCVX) conducted the offering with underwriters BofA Securities, Inc., Jefferies LLC, Leerink Partners LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C..
The company sold 10.2 million shares of common stock and pre-funded warrants to purchase 2.4 million shares of common stock in the offering. The shares sold at a public offering price of $103 a share, while the warrants sold at $102.99 per warrant. The stock closed Thursday at $112.10.
The underwriters further agreed to purchase an additional 1.9 million shares of common stock.
Vaxcyte specializes in developing treatments for bacterial diseases.
The stock has gained 79% in the year to date, while the S&P 500 has gained 14%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-06-24 1248ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks